课题基金 / 基金详情

Discovery and Evaluation of Prioritized Mutations in Pancreatic Cancer

Discovery and Evaluation of Prioritized Mutations in Pancreatic Cancer
胰腺癌优先突变的发现和评估
批准号:
7651546
负责人:
SCOTT E KERN
金额:
$29.12万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-04-01 至 2014-03-31
关键词:
ActivinsAdultAffectAlternative SplicingApoptosisApoptoticBRCA2 geneBindingBiological AssayCancer FamilyCell CycleCellsCharacteristicsChromosomal InstabilityChromosome MappingClassificationCloningComplementComplexConsensusDatabasesDeletion MutationDevelopmentDistantDominant GenesDrug or chemical Tissue DistributionEvaluationEventExhibitsFollow-Up StudiesFoundationsFundingFunding AgencyFutureGene ExpressionGene ProteinsGene TargetingGenesGenomeGenomic InstabilityGoalsHereditary DiseaseHumanImpairmentIn SituIn VitroIncidenceKnock-outKnowledgeLibrariesMADH4 geneMaintenanceMalignant NeoplasmsMalignant neoplasm of pancreasMapsMediatingMethodsMissense MutationModelingMolecularMutateMutationNeoplasm MetastasisNeoplasmsOncogenesOrganPAWR proteinPancreasPatternPredispositionPrincipal InvestigatorPublicationsPublishingRNA SplicingRecessive GenesRecombinantsRegulatory PathwayResearchResourcesRestRoleSeedsSignal PathwaySiteSmall Interfering RNASomatic CellSomatic MutationSourceSpecific qualifier valueSpecificitySurveysSystemTechniquesTechnologyTertiary Protein StructureTissuesTranscriptTransforming Growth Factor betaTriageTumor Suppressor GenesUnited States National Institutes of HealthVariantXenograft procedureZebrafishcancer cellcancer genomecellular engineeringdensitydisease-causing mutationexperiencegenome-widehigh riskhomologous recombinationhuman tissuein vivoloss of function mutationmutantneoplasticneoplastic cellnew technologynovelpancreatic neoplasmpancreatic tumorigenesispolyclonal antibodyprotein functionreceptorresearch studysuccesstooltranscription factortumortumorigenesiszebrafish development

项目摘要

项目成果

SCOTT E KERN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
A mechanistic understanding of cancer rests heavily upon the mutated genes. These include genes causing familial tumor susceptibilities, governing replication fidelity, and residing in regulatory pathways. Pancreatic cancer is an unusually efficient system in which to identify distinctive mutational targets, discoveries to which our research group has contributed heavily. This success is due in part to highly informative structural patterns of homozygous deletions as well as a higher incidence of genome- maintenance mutations (especially those affecting homologous recombination) in this tumor type. Indications are that many recessive genes and perhaps additional dominant genes remain to be discovered in pancreatic cancer. Most of the high-risk pancreatic cancer families remain unexplained by known mutations, and most cancers having CIN (chromosomal instability) are not yet tied mechanistically to a molecular cause. Recessive mutations in novel genes, for example, are currently being discovered more rapidly than can be annotated for their functional significance. We recently explored and published key technical breakthroughs and special tumor cell resources that are newly available and can quickly accelerate this line of study. Powerful high-throughput sequencing techniques are underway to aid such studies, but will need to be complemented by a roadmap derived from a strategic structural analysis of the cancer genome such as we are developing. Our specific aims will locate promising sites of new mutant genes. For genes having some existing functional clues, we can assess the effects of mutation using available assays. For truly novel genes having few clues as to their function, we can achieve missense mutations or gene disruption using technologies we developed for homologous recombination in somatic cells, with phenotypic assessment accomplished both by gene-specific assays and by orthotopic xenografting. For genes having unknown functional assignment and distant evolutionary conservation, a zebrafish model of gene impairment will be used to survey for developmental clues to function and for an ability to augment zebrafish pancreatic tumorigenesis. This latter technique seems surprising, but appears to offer immense efficiency for classifying novel genes. Our long-term goal is to provide a more complete foundation for future studies of familial susceptibility, disrupted signaling pathways, and genome instability in pancreatic cancer. RELEVANCE (Seeinstructions): Pancreatic cancer is a genetic disease caused by mutations. We identified frequent mutations in the p16, SMAD4, BRCA2, and other genes, explaining the causes of many cases of familial forms of pancreatic cancer. We now need to efficiently survey large numbers of mutated genes arising through new technologies. These genes and techniques will be explored in this project
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Discovery and Evaluation of Prioritized Mutations in Pancreatic Cancer
  • 批准号:
    8464660
  • 项目类别:
  • 资助金额:
    $32.93万
  • 财政年份:
    2013
  • 负责人:
    SCOTT E KERN
  • 依托单位:
High-throughput analysis of pancreatic cancer mutations
  • 批准号:
    7842654
  • 项目类别:
  • 资助金额:
    $25.52万
  • 财政年份:
    2009
  • 负责人:
    SCOTT E KERN
  • 依托单位:
High-throughput analysis of pancreatic cancer mutations
  • 批准号:
    8193244
  • 项目类别:
  • 资助金额:
    $24.76万
  • 财政年份:
    2009
  • 负责人:
    SCOTT E KERN
  • 依托单位:
High-throughput analysis of pancreatic cancer mutations
  • 批准号:
    8258792
  • 项目类别:
  • 资助金额:
    $24.76万
  • 财政年份:
    2009
  • 负责人:
    SCOTT E KERN
  • 依托单位:
海外基金